Malika Bilal
speaker
38 appearances
1 recordings
1 series
first heard Jan 2026
last heard 16 Jan
Malika Bilal’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jan 2026 with 1.
Appearances
And... There were two scientists who were noticing that type 2 diabetics were often people living with obesity.
And so when they saw this weight loss, they thought, oh my gosh, we would not just be a treatment company, we would be a prevention.
A lot of people think that these drugs really just came out in the past few years and don't think too much about the development so it really kind of goes back to the 1980s when
There was two teams, one in Mass General in Boston and one in the University of Copenhagen, that were essentially in this sort of arms race trying to, first of all, find this GLP-1, which is the secret sauce in Ozempic and Manjaro and all these other drugs that people are now using for diabetes and weight loss.
Trying to prove, first of all, that it existed.
So it was like a concept thing.
And then also to prove that it helped to reduce blood sugar.
And it was just from that early stage that they managed to do all of that.
And as it went into the pharmaceutical development, it was when they really started to see the weight loss, which they really just saw as a side effect, not the purpose of these drugs.
Well, Novo Nordisk is the company that makes Ozempic and Wegovy is the obesity medication.
So they were like the titan of insulin and diabetes.
And there were two scientists working in Novo Nordisk who were really noticing, first of all, that obesity levels were rapidly increasing throughout the world and also that their patients, so the type 2 diabetics, were often people living with obesity.
And so when they saw this weight loss, they thought, oh, my gosh, we would not just be a treatment company.
We would be a prevention.
And they got very, very excited about that.
But unfortunately, there was a very big stigma around obesity and the causes of it.
And even the executives in Nova Nordisk, you know, really kind of thought this has nothing to do with us.
This has nothing to do with pharmaceuticals.
This is really a lifestyle thing.
These are choices that people are making.
Showing 1–20 of 38 · page 1 of 2
Next →